On this basis, three CDK4/6 inhibitors, namely palbociclib (73), ribociclib (74), and abemaciclib (75) have been FDA approved in combination with endocrine therapy for the first- or second-line treatment of ER+ HER2- advanced BC (Figure 2). Here, CDK4 is linked to breast cancer.